Tuesday, 23 Apr 2019

You are here

Ankylosing Spondylitis Women Show Less Durable Responses to TNF Inhibitors

A study from the Netherlands has shown that the long-term drug survival of TNF inhibitors differ between men and women, with women having a lower long-term retention rate compared to men.  (Citation source: http://bit.ly/2KZQ0DJ)

A single-center, retrospective study of 122 anklylosing spondylitis (AS) patients, analyzed the outcomes of those receiving either  etanercept, adalimumab, or infliximab between 2004 and 2014.

Nearly 40% were women and most AS patients received adalimumab (59.7%), compared to etanercept (28.9%) or infliximab (11.3%).

This 10-year analysis (mean follow-up duration was 5.1 years) showed several interesting results:

  • the best TNFi survival rate with etanercept (85.3% after 3.7 years), followed by adalimumab and infliximab.
  • 17.2% eventually stopped TNFi without starting a new therapy,
  • 26.2% stopped their TNFi and then switched to another anti-TNF agent.
  • TNFi discontinuation were due to inefficacy (52.4%), vollowed by adverse events, especially infections.
  • Women had significantly lower treatment survival than men (women 33.4 mos versus men 44.9 mos (P = .031)
  • Women switched to another drugy more frequently than men (26.9% vs 16.3%)
  • Women were more likely to completely stop anti-TNF therapy (vs. men) (20.8% vs 14.9%, not significant).

 Factors that drive these differences will require further study. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Higher Comorbidities in Hidradenitis Suppurativa

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed. 

AAD/NPF Guidelines on Biologic Use in Psoriasis

Menter and colleagues from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) have published their expert consensus guidelines for the use of biologics in psoriasis.

Dermatology Guidelines for Psoriatic Comorbidities

The JAAD has published joint guidelines from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) on the approach, management and dermatolgist roles for select comorbid conditions.